Edward W. Boyer, MD, PhD, University of Massachusetts Medical School, Worcester, MA.
Walter C. Prozialeck, PhD, Midwestern University, Downers Grove, IL.
Saruta Majumdar, PhD, Memorial Sloan-Kettering Cancer Center, New York.
Petition.whitehouse.gov: “Please do not make Kratom a Schedule I Substance.”
Boyer, E., Addiction, June 2008.
Prozialeck, W. The Journal of the American Osteopathic Association, December 2012.
Majumdar, S. Journal of Medicinal Chemistry, Sept. 2, 2016.
Centers for Disease Control and Prevention, Morbidity and Mortality Weekly Report, July 29, 2016 “Notes from the Field: Kratom (Mitragyna speciosa) Exposures Reported to Poison Centers — United States, 2010–2015.
U.S. Drug Enforcement Administration, Drugs of Abuse: A DEA resource guide and “DEA Announces Intent to Schedule Kratom.”
Russ Baer, spokesman, DEA.
Huffington Post: “Congress Calls Out DEA For Unilateral Move To Expand The War On Drugs.”
Federal Register: “Withdrawal of Notice of Intent to Temporarily Place Mitragynine and 7- Hydroxymitragynine into Schedule I.”
News release, the American Kratom Association, and the Botanical Education Alliance.